Please select the option that best describes you:
What are your top takeaways in Hematologic Malignancies from ASH 2025?
Answer from: at Academic Institution
Abstract 645 - Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial: As blinatumomab becomes increasingly incorporated into the frontline treatment of B-cell ALL, it is vitally important to assess inotuzumab ozogamicin (InO)-based therapies in the relaps...
Sign In or Register to read more
Answer from: at Community Practice
The PARADIGM study in the plenary session obviously which stirred a lot of controversy.
I see this work as potentially a step towards intensive chemo-free induction for many AML patients but with lots of reservations:
Generalizing HMA/Ven for all fit/young patients with high-risk dis...
Answer from: at Community Practice
AML - Promise with use of HMA venetoclax as a bridge to transplant even in young and fit patients (age <60 who are not NPM1 mutated, not FLT3 mutated, and do not have CBF leukemia) based on a paradigm phase 2 randomized multicenter study.
AML - use of triplets with IDH1 inhibitor or menin inhi...